Antimicrobial Agents in Prevention and Treatment of Oral Diseases

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: 31 March 2025 | Viewed by 1245

Special Issue Editor


E-Mail Website
Guest Editor
Department of Periodontology School of Dental Medicine University of Bern, Bern, Switzerland
Interests: antimicrobial therapy in dentistry; biofilms; antibiotics; alternatives to antibiotics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Special Issue “Antimicrobial agents in Prevention and Treatment of Oral Diseases” focuses on the use of antimicrobial agents in oral healthcare. Antimicrobial agents, including antiseptics, antibiotics and antifungals are commonly used to prevent and treat oral diseases, such as caries, periodontitis, and oral infections. The effectiveness of these agents in oral healthcare is a topic of ongoing research and debate, as their use can lead to the development of antimicrobial resistance and other adverse effects.

The Special Issue also covers a wide range of topics related to antimicrobial agents in oral healthcare, such as the efficacy of specific antimicrobial agents in preventing and treating oral diseases, and the safety and potential side effects of these agents. Additionally, we welcome submissions focusing on the development of new antimicrobial agents for use in oral healthcare.

Prof. Dr. Sigrun Eick
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • periodontitis
  • candidiasis
  • antibiotics
  • antiseptics
  • adverse effects
  • development of resistance

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 6154 KiB  
Article
Preclinical Validation of MIN-T: A Novel Controlled-Released Formulation for the Adjunctive Local Application of Minocycline in Periodontitis
by Małgorzata Benedyk-Machaczka, Piotr Mydel, Karsten Mäder, Marta Kaminska, Nadine Taudte, Marcel Naumann, Martin Kleinschmidt, Sandra Sarembe, Andreas Kiesow, Sigrun Eick and Mirko Buchholz
Antibiotics 2024, 13(11), 1012; https://doi.org/10.3390/antibiotics13111012 - 28 Oct 2024
Viewed by 883
Abstract
Background: Adjunctive treatment of periodontitis lacks solutions which allow for enough time for wound healing in the periodontal pockets by avoiding fast re-colonization. Such a solution might be an antibiotic-containing formulation with a controlled release over a period of weeks. Here, a recently [...] Read more.
Background: Adjunctive treatment of periodontitis lacks solutions which allow for enough time for wound healing in the periodontal pockets by avoiding fast re-colonization. Such a solution might be an antibiotic-containing formulation with a controlled release over a period of weeks. Here, a recently described minocycline-containing approach is qualified for further clinical development by focusing on proof-of-concept, systemic burden, resistance development, and degradation studies. Methods: Animal studies were done in two different (mouse-chamber, rat Porphyromonas gingivalis challenging) models, including effects on inflammation markers, bone loss, and bone structure. Also, serum concentrations of minocycline after local application were determined by HPLC-MS/MS. The resistance status of bacterial clinical isolates against minocycline was investigated and the degradation of the formulation was characterized by laser scanning and scanning electron microscopy. Results: Animal studies clearly demonstrated the applicability of the new formulation in the investigated models. Inflammation markers decreased in a dose-dependent manner and reduced bone loss compared to non-treated group was observed. Therefore, the systemic burden of the antibiotic was neglectable. Minocycline is still effective against oral pathogens; resistance development was not seen. The biodegradable thread was first swollen and subsequently degraded over a period of weeks. Conclusions: The results support the continued clinical development of this new formulation. A phase I clinical trial is planned to further evaluate its safety and efficacy. Full article
(This article belongs to the Special Issue Antimicrobial Agents in Prevention and Treatment of Oral Diseases)
Show Figures

Graphical abstract

Back to TopTop